INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Sethuraman Natarajan sold TRDA

President, Research & Develop. · Entrada Therapeutics, Inc. · Common Stock

Side
SELL
Value
$399K
Shares
25.9K
Price
$15.39
Executed
May 4, 2026
Disclosed
May 4, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
May 4 executedMay 4, 2026 disclosed

TRDA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+11 / 25

    $399K reported value · 10.7% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TRDA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    23
    PK
    Parmar KushDirector
    TRDAEntrada Therapeutics, Inc.
    Open-market sale
    		SELL$647K
    92.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    24
    PK
    Parmar KushDirector
    TRDAEntrada Therapeutics, Inc.
    Open-market sale
    		SELL$73K
    10.5K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    23
    PK
    Parmar KushDirector
    TRDAEntrada Therapeutics, Inc.
    Open-market sale
    		SELL$358K
    52.3K sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RM
    Radhakrishnan MahaDirector
    TRDAEntrada Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 10, 2026Jun 12, 2026
    traded Jun 10, 2026
    		+2dSEC FORM 4

    Evidence

    17
    DJ
    Dowden Nathan JPresident & COO
    TRDAEntrada Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$230K
    15.0K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    7
    DJ
    Dowden Nathan JPresident & COO
    TRDAEntrada Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    15.0K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    3
    DJ
    Dowden Nathan JPresident & COO
    TRDAEntrada Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$26K
    15.0K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001873394-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 4, 2026
    Published
    May 4, 2026
    Ingested by INSIDER
    Nov 5, 04:01 UTC
    Last re-read
    Nov 5, 04:01 UTC

    Extracted facts

    Filer
    Sethuraman Natarajan
    Role
    President, Research & Develop.
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Entrada Therapeutics, Inc.
    Ticker
    TRDA
    Shares
    25.9K
    Price per share
    $15.39
    Value
    $398,810
    Execution date (reported)
    May 4, 2026
    Owned after transaction
    216.3K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 25.9K
    • Price: $15.3939

    = $398,810

    What this establishes

    Sethuraman Natarajan filed this Form 4 reporting a open-market sale of TRDA on May 4, 2026. It became public on May 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    President, Research & Develop.
    Sethuraman Natarajancik:0001873394
    Issuer
    Entrada Therapeutics, Inc.cik:0001689375

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.